Telix Pharmaceuticals Limited (ASX: TLX), a company from the health care sector, is engaged in the development and commercialization of molecularly targeted radiation products for the treatment of cancer.
On 26 April 2019, Telix Pharmaceuticals Limited (ASX: TLX) notified its investors that Fractionated Prostate Cancer Therapy data has been published which will have significant treatment benefit to the patients. The development of the TLX591 (Prostate Therapy) was supported by the clinical data obtained for 177Lu-huJ591 by prostate cancer researchers at Weill Cornell Medical College (WCMC) and collaborators.
The recent phase II of the data showed that fractionated (low dose, repeat dose) administration of 177Lu-huJ591 was able to reduce the hematologic toxicity significantly. Phase II delivered demonstrable anti-tumour response as well as survival benefit to men who were diagnosed with advanced castrate-resistant metastatic prostate cancer (mCRPC).
There were forty-nine men who suffered from metastatic castrate-resistant prostate cancer (mCRPC) and were given fractionated (repeat) doses of 177Lu-J591 in the range from 20 to 45 mCi/m2 ×2, two weeks apart. The therapy given to these men was well-tolerated. The toxicity was reversible (transient) neutropenia and thrombocytopenia at the highest dose of 45 mCi/m2 ×2. No exocrine gland (salivary/lacrimal) targeting was observed during the phase.
The highest dose reflected the greatest decrease in the level of prostate-specific antigen along with the longest survival.
Out of the total patients, 80% of the patients reported positive imaging of prostate-specific membrane antigen (PSMA). The remaining who had less intense PSMA imaging were inclined to have a poorer response and these patients were selected for therapy.
Through the fractionated administration of 177Lu-J591 allowed dosing of advanced cumulative radiation that had fewer side effects as compared to its previous single-dose escalation data.
The highest dose was able to deliver significant anti-tumour effect where the median survival of 42.3 months existed at 95% confidence level.
The results of the fractionated data of phase I and phase II that was published was based on 200 patients who were treated till date. Since the fractionated approach was able to reduce toxicity while delivering durable treatment response from the patients of mCRPC, the data obtained would further help the company in developing prostate therapy program of the company (TLX591).
Also read: The non-deal roadshow of Telix for March-April 2019.
For the year ended 31 December 2018, the company incurred a loss of $13,829,825. The balance sheet of the company reported an increase in the net asset base as a result of growth in the total asset during the period. The total shareholders’ equity by the end of the period was $52,904,410.
There was a decrease in the net cash held by the company as a result of increased cash outflow through operating and investing activities. By the end of the FY2018, the net cash and cash equivalents with the company were at $25,771,055.
In the last six months, the shares of TLX have generated a negative return of 4.84%. The YTD performance of the stock has improved where the stock has given a return of 36.15%.
The TLX stock closed the market trading at A$0.910, up 2.83% on 26 April 2019. TLX holds a market capitalization of A$193.25 million to date and has approximately 218.37 million outstanding shares.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.